News
NVO
40.85
+0.10%
0.04
Should You Forget CVS Health and Invest in a Purer Healthcare Play?
The Motley Fool · 1h ago
Walmart Stock (WMT) Flattens Despite Expanding Weight Loss Drug Services
TipRanks · 2h ago
Novo Nordisk Maps Heart Risk in New Diabetes Patients Across Southeast Asia
TipRanks · 2h ago
Walmart expands access to weight management support services
TipRanks · 3h ago
Hims rises as FDA considers broader peptides access; analysts see long-term win
Reuters · 3h ago
Novo Nordisk has reportedly added 2,000 to workforce this year
Seeking Alpha · 5h ago
BUZZ-U.S. STOCKS ON THE MOVE-Abbott, PepsiCo, Blue Owl
Reuters · 6h ago
Hims & Hers Health Stock Rallies on Regulatory Pivot. It's Not About GLP-1s This Time.
Barron‘s · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-Hamilton Lane, Meta, Marsh
Reuters · 7h ago
BUZZ-Novo Nordisk rises after weekly obesity pill prescription data
Reuters · 8h ago
Hims & Hers on track to extend gains as RFK Jr. seeks to loosen peptide regulations
Seeking Alpha · 10h ago
Prediction: This 1 Thing Could Cement Eli Lilly's Leadership in the Billion-Dollar Weight Loss Drug Market
The Motley Fool · 11h ago
Indian's Hetero targets annual sales of 1.5 mln semaglutide pens in global rollout
Reuters · 11h ago
REFILE-India's Hetero targets annual sales of 1.5 mln semaglutide pens in global rollout
Reuters · 11h ago
The Zacks Analyst Blog Highlights Netflix, PepsiCo, Novo Nordisk, Hawthorn Bancshares and Park Aerospace
NASDAQ · 11h ago
Quick-Service Restaurants Take Biggest Hit as GLP-1 Users Pare Visits, Survey Says -- Market Talk
Dow Jones · 20h ago
Top Research Reports for Netflix, PepsiCo & Novo Nordisk
NASDAQ · 21h ago
Lilly Stock Dips on FDA Request for More Foundayo Safety Data. Is the Market Reaction Overblown?
Barron‘s · 23h ago
The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust
The Motley Fool · 1d ago
FDA sets up AdCom meeting to decide on lifting restrictions on certain peptides
Seeking Alpha · 1d ago
More
Webull provides a variety of real-time NVO stock news. You can receive the latest news about Novo-Nordisk A/S through multiple platforms. This information may help you make smarter investment decisions.
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.